Trade

with

Chemocentryx Inc
(NASDAQ: CCXI)
AdChoices
5.69
+0.13
+2.34%
After Hours :
5.69
0.00
0.00%

Open

5.72

Previous Close

5.56

Volume (Avg)

154.67k (82.48k)

Day's Range

5.50-5.80

52Wk Range

4.09-8.25

Market Cap.

240.95M

Dividend Rate ( Yield )

-

Beta

1.18

Shares Outstanding

43.34M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 6.06M

    • Net Income

    • -38.67M

    • Market Cap.

    • 240.95M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,903.60

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.18

    • Forward P/E

    • -

    • Price/Sales

    • 106.38

    • Price/Book Value

    • 1.89

    • Price/Cash flow

    • -7.30

      • EBITDA

      • -38.04M

      • Return on Capital %

      • -28.03

      • Return on Equity %

      • -29.71

      • Return on Assets %

      • -28.03

      • Book Value/Share

      • 2.94

      • Shares Outstanding

      • 43.34M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -66.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -1,903.60

            • 39.38

            • Net Profit Margin

            • -1,903.60

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -273.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -273.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.72

              • 2.92

              • Quick Ratio

              • 12.61

              • 2.35

              • Interest Coverage

              • -971.14

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 2.94

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.37

                • 277.78

                • P/E Ratio 5-Year High

                • -17.84

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.11

                • 124.82

                • Price/Sales Ratio

                • 102.04

                • 9.35

                • Price/Book Value

                • 1.82

                • 8.50

                • Price/Cash Flow Ratio

                • -7.30

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -29.71

                    (-12.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -28.03

                    (-11.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -29.60

                    (-12.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -39.12M
                  Operating Margin
                  -645.46
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.30
                  Ownership

                  Institutional Ownership

                  70.13%

                  Top 10 Institutions

                  60.91%

                  Mutual Fund Ownership

                  25.45%

                  Float

                  45.18%

                  5% / Insider Ownership

                  5.32%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • VA CollegeAmerica Small Cap World

                  •  

                    3,426,800

                  • 0.00

                  • 7.91

                  • Wasatch Small Cap Growth Fund

                  •  

                    1,357,191

                  • 0.00

                  • 3.13

                  • Franklin Biotechnology Discovery

                  •  

                    1,313,189

                  • 153.32

                  • 3.04

                  • Franklin Biotechnology Discovery Fund

                  •  

                    595,308

                  • 0.00

                  • 1.37

                  • iShares Nasdaq Biotechnology

                  •  

                    575,268

                  • -0.69

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    436,660

                  • -1.01

                  • 1.20

                  • Vanguard Total Stock Mkt Idx

                  •  

                    407,910

                  • 0.00

                  • 0.94

                  • Harbor Small Cap Growth Fund

                  •  

                    406,522

                  • -2.78

                  • 0.94

                  • iShares Russell 2000 Value

                  •  

                    184,530

                  • 0.35

                  • 0.51

                  • Putnam Global Health Care Fund

                  •  

                    180,888

                  • 0.00

                  • 0.42

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Bvf Inc

                  •  

                    8,181,816

                  • +4.94%

                  • 18.88

                  • Capital World Investors

                  •  

                    3,426,800

                  • 0.00%

                  • 7.91

                  • Balyasny Asset Management LLC

                  •  

                    2,753,650

                  • +20.22%

                  • 6.35

                  • Wasatch Advisors Inc.

                  •  

                    2,595,950

                  • -0.42%

                  • 5.99

                  • Franklin Advisers, Inc.

                  •  

                    1,908,497

                  • 0.00%

                  • 4.40

                  • Westfield Capital Management Company, LP

                  •  

                    1,400,993

                  • -0.09%

                  • 3.23

                  • BlackRock Fund Advisors

                  •  

                    1,162,397

                  • -4.25%

                  • 2.68

                  • Broadfin Capital, LLC

                  •  

                    1,050,000

                  • 0.00%

                  • 2.42

                  • ALTA BIOPHARMA MANAGEMENT III LLC

                  •  

                    833,499

                  • -54.35%

                  • 1.94

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune di...moreseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibod...morey, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn’s disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA’s current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.lessless

                  Key People

                  Dr. Thomas J. Schall, PhD

                  CEO/Chairman of the Board/Director/Founder/President

                  Ms. Susan M. Kanaya

                  CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional

                  Dr. Roger C. Lucas, PhD

                  Director

                  James L. Tyree

                  Director

                  Dr. Joseph M. Feczko

                  Director

                  • Chemocentryx Inc

                  • 850 Maude Avenue

                  • Mountain View, CA 94043

                  • USA.Map

                  • Phone: +1 650 210-2900

                  • Fax: +1 650 210-2910

                  • chemocentryx.com

                  Incorporated

                  1996

                  Employees

                  60

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: